drugset
drugset / Trial / NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432 ↗

Phase 1 Recruiting 470 enrolled SystImmune Inc.
RandomizedSequentialOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Timeline

Start
2023-08-08
Primary completion
2026-12-31
Completion
2028-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Izalontamab Brengitecan Unknown — Intravenous

Indications

cervical cancer endometrial cancer esophageal cancer head and neck squamous cell carcinoma nasopharyngeal carcinoma non-small cell lung carcinoma ovarian cancer prostate adenocarcinoma small cell lung carcinoma triple-negative breast carcinoma